Since many years; multiple belt system is being used. The characteristics of multiple belts and pulley system comprises of an algorithm that develops the linear equations of motion for multiple belt systems. Equations of motion are formulated by the computer program developed by this algorithm. This could be thought of as sets of simple belt […]

Dr. Peush Bajpai | Multiple Myeloma | Manipal Hospitals Delhi “Multiple Myeloma is a Hematologic malignancy of Plasma cells which are found basically in the blood, and are produced in the bone marrow. It is caused when cancerous ‘chaotic elements’ are produced in plasma cells. The treatment nowadays is done through Targeted and Plasma Modulation […]

Global Multiple Myeloma Market Is Booming Globaly | Most recent Report with Analysis | Future … The global Multiple Myeloma market research report offers all the vital data in the domain. The latest report assists new bees as well as established market participants to analyze and predict the Multiple Myeloma market at the regional as well as […]

Bone Cancer Drug Market 2020 Disclosing Latest Trends and Advancement Outlook 2026 Along … Another business knowledge report released by Data Bridge Market Research with title “Worldwide Bone Cancer Drug Market Status and Forecast (2019-2026) by Region, Product Type and End-Use” has capacities to raise as the most huge market worldwide as it has remained […]

Amgen : BiTE® 101 Cancer treatments have traditionally fit into one of three categories: chemotherapy, surgery or radiation. In recent years, new approaches and innovative modalities – such as immuno-oncology or therapies targeting specific genetic mutations – have started to reshape how oncologists think about treating many cancers. Amgen has been serving cancer patients for […]

Venclexta With Velcade and Dexamethasone May Improve Progression-Free Survival in Relapsed … Treatment with Venclexta (venetoclax), in addition to Velcade (bortezomib) and dexamethasone, significantly improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (MM) compared with placebo, according to results of the BELLINI trial published in The Lancet Oncology. Despite this significant […]

Maintenance therapy following salvage ASCT for multiple myeloma Ravi Vij, MD, MBA, Washington University Medical School, St Louis, MO, discusses maintenance therapy following salvage autologous stem cell transplant (ASCT) in patients with multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for … Preliminary data from the Phase 1 trial are expected first half 2021 Additional €3.4 million in non-dilutive funding from SPW-Recherche of the Walloon Region to support advancement of CYAD-211 MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) — Celyad Oncology […]

Liposomal Doxorubicin Market Quality & Quantity Analysis | Johnson & Johnson, Sun … North America, Europe, China, Japan, Rest of the World, September 2020,– – The Liposomal Doxorubicin Market research report includes an in-sight study of the key Global Liposomal Doxorubicin Market prominent players along with the company profiles and planning adopted by them. This helps the buyer of the […]

Antengene submits NDAs for XPOVIO (Selinexor) in multiple APAC markets Aims to treat adult patients with “relapsed or refractory multiple myeloma (rrMM)” and “relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL)” in Singapore, Australia, Hong Kong and South Korea Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class […]